I was pleased to see that some progress is finally being made in the HBV program, even though some of the info was already known. As far as the TT-034 program is concerned, I would have liked to have see the consolidated information from cohort one confirming shrna circulation and I would have liked to have seen the AAV/hepatocyte transfection rates but it was not to be. The data from the first patient could have been atypical and so the additional data from the second patient would have been a useful confirmation. Not releasing this information, however, is not necessarily a bad thing. The company may well be being conservative but it does make one wonder what level of information will be provided in the future at the completion of the other cohorts. I mean, a statement like, "cohort four dosing was safe and reduced the viral load" would be pretty meaningless unless the actual viral load reduction was stated and number of patients in the cohort with the reduction was referenced. I guess we will just have to be a little more patient.
I notice that the Tribetarna trial still has no estimated start date. Again, this could be the company being more circumspect - given their previous track record at forecasting dates.
In reality, this event was not a milestone for long investors. The next real milestone will be when efficacy is announced (unless a deal comes out of left field) and that will be months away. Until then, unless one wants to trade short as well, best not to look at the daily price movements as they are unfathomable.
BLT Price at posting:
87.5¢ Sentiment: None Disclosure: Held
